The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI was launched in 2008 as a public-private partnership (PPP) between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
IMI approaches its 10th anniversary and is organizing its 1st Scientific Symposium on the 22nd and 23rd of October 2018 in Brussels. Since 2008, IMI has launched almost 100 projects, all of which take a collaborative, open, innovative approach to some of the biggest challenges in medical research and drug development today. With 53 partners and a budget of 40 million euros, HARMONY is IMI's largest big data project and we are proud to be part of the IMI 'family'.
Main objectives of the 1st IMI Scientific Symposium are:
____
____
Relevant links:
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
